Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing

This article was originally published here

Based on these results the compound has been advanced to Phase I clinical testing alone and in combination with trametinib in patients with different types of advanced solid

The post Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply